Pineal hormone melatonin as an adjuvant treatment for COVID-19 (Review)

被引:25
作者
Vlachou, Marilena [1 ]
Siamidi, Angeliki [1 ]
Dedeloudi, Aikaterini [1 ]
Konstantinidou, Sofia K. [2 ,3 ]
Papanastasiou, Ioannis P. [4 ]
机构
[1] Natl & Kapodistrian Univ Athens, Div Pharmaceut Technol, Dept Pharm, Sch Hlth Sci, Athens 15784, Greece
[2] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Dept Propaedeut Internal Med 1, Athens 11527, Greece
[3] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Diabet Ctr, Athens 11527, Greece
[4] Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Dept Pharm, Div Pharmaceut Chem, Athens 15784, Greece
关键词
SARS-CoV-2; COVID-19; melatonin; pineal hormone; mechanism of action; clinical trials; OXIDATIVE STRESS; SURVIVAL RATE; ILL PATIENTS; VENEZUELAN; EXPRESSION; APOPTOSIS; BRAIN; PEROXIDATION; INFLAMMATION; MYOCARDITIS;
D O I
10.3892/ijmm.2021.4880
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The beneficial properties of the pineal hormone, melatonin, as a neuroprotective and cardioprotective agent, have been previously identified. Furthermore, melatonin plays essential roles in biological rhythms resynchronization, sleep initiation/maintenance and metabolic, ocular, rheumatological diseases. In addition to these functions, melatonin is known to exert immunomodulation, anti-inflammatory and anti-oxidative effects. Due to these properties, coupled with its non-toxic nature, melatonin has been suggested to limit viral infections; however, melatonin cannot be classified as a viricidal drug. In addition, the recent increase in the number of clinical trials on melatonin's role, as an adjuvant treatment for COVID-19, has resurged the interest of the scientific community in this hormone. The present short review aimed to improve the understanding of the antiviral/anti-COVID-19 profile of melatonin and the clinical trials that have recently been conducted, with respect to its co-administration in treating individuals with COVID-19.
引用
收藏
页数:9
相关论文
共 85 条
[1]   Clinical trial to test the efficacy of melatonin in COVID-19 [J].
Acuna-Castroviejo, Dario ;
Escames, Germaine ;
Figueira, Juan C. ;
de la Oliva, Pedro ;
Borobia, Alberto M. ;
Acuna-Fernandez, Carlos .
JOURNAL OF PINEAL RESEARCH, 2020, 69 (03)
[2]   Pulmonary prophylactic impact of melatonin and/or quercetin: A novel therapy for inflammatory hypoxic stress in rats [J].
Al-Rasheed, Nouf M. ;
Fadda, Laila ;
Attia, Hala A. ;
Sharaf, Iman A. ;
Mohamed, Azza M. ;
Al-Rasheed, Nawal M. .
ACTA PHARMACEUTICA, 2017, 67 (01) :125-135
[3]   Structural and physico-chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding with novel coronavirus proteins [J].
Al-Zaqri, Nabil ;
Pooventhiran, T. ;
Alsalme, Ali ;
Warad, Ismail ;
John, Athira M. ;
Thomas, Renjith .
JOURNAL OF MOLECULAR LIQUIDS, 2020, 318
[4]  
[Anonymous], EU Clinical Trials Register
[5]   ACUTE PHARMACOLOGY OF MELATONIN [J].
BARCHAS, J ;
DACOSTA, F ;
SPECTOR, S .
NATURE, 1967, 214 (5091) :919-&
[6]   Melatonin for the treatment of sepsis: the scientific rationale [J].
Biancatelli, Ruben Manuel Luciano Colunga ;
Berrill, Max ;
Mohammed, Yassen H. ;
Marik, Paul E. .
JOURNAL OF THORACIC DISEASE, 2020, 12 :S54-S65
[7]   Effects of antioxidants on surfactant peroxidation by stimulated human polymorphonuclear leukocytes [J].
Bouhafs, RKL ;
Jarstrand, C .
FREE RADICAL RESEARCH, 2002, 36 (07) :727-734
[8]   Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial [J].
Bourne, Richard S. ;
Mills, Gary H. ;
Minelli, Cosetta .
CRITICAL CARE, 2008, 12 (02)
[9]   Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection [J].
Cain, Matthew D. ;
Salimi, Hamid ;
Gong, Yongfeng ;
Yang, Lihua ;
Hamilton, Samantha L. ;
Heffernan, James R. ;
Hou, Jianghui ;
Miller, Mark J. ;
Klein, Robyn S. .
JOURNAL OF NEUROIMMUNOLOGY, 2017, 308 :118-130
[10]  
Carlberg C, 2000, ANN NY ACAD SCI, V917, P387